Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

  • End date
    Mar 1, 2026
  • participants needed
  • sponsor
    Tang-Du Hospital
Updated on 9 July 2022
lung carcinoma


In this open-label, single-arm, phase 2 study, 40 eligible patients with EGFR mutated stage IIIA-IIIB resectable NSCLC will be recruited to receive furmonertinib for 9 weeks combined with cisplatin/pemetrexed for 3 cycles (21 d/cycle) as neoadjuvant therapy before radical surgery. Radiological and pathological evaluations will be performed before and after the neoadjuvant therapy to assess the efficacy of treatment. Adverse events during neoadjuvant therapy, disease and survival status will also be collected in the study.

Condition Non-small Cell Lung Cancer
Treatment Furmonertinib+cisplating/pemetrexed
Clinical Study IdentifierNCT05430802
SponsorTang-Du Hospital
Last Modified on9 July 2022


Yes No Not Sure

Inclusion Criteria

With written informed consent before any study procedure
Histology or cytology diagnose of non-small cell lung cancer within 60 days
Stage IIIA/IIIB, with resectable lesion(s) by radiology
EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)
Without prior anti-tumor treatment
With at least one measurable lesions (The longest axis ≥10mm)
ECOG performance status 0-1
Using adequate and effective contraception, women should refrain from breastfeeding and have a negative pregnancy test prior to the first administration of the study drug if within during child-bearing age

Exclusion Criteria

EGFR Exon 20 insertions positive
Mixed with small cell cancer, or other mixed types of lung cancer
Any prior anti-tumor treatment
Major surgery within 4 weeks before enrolment
Women with pregnancy or breastfeeding
Use of strong CYP3A4 inhibitors within 7 days or strong CYP3A4 inducers within 21 days before enrolment; use of traditional Chinese medicine with anti-tumor effect within 21 days before enrolment
With history of other malignancy except for radical resected tumors without recurrence for 5 years or more
With severe or uncontrolled systemic disease such as uncontrolled hypertention, diabetes mellitus, chronic heart failure, unstable angina, myocardial infarction within 1 year, active hemorrhage, active HBV/HCV/HIV or other infections requiring infusion treatment
Severe gastrointestinal diseases which may affect the intake and absorption of study drug
Prolongation of ECG QTc or with relative risk factors
History of interstitial lung disease or with relative risk factors
Inadequate organ function of hematology, liver and kidney
Allergic to study drugs or any component
Poor adherence or other situation judged by investigator
Patients who had participated other clinical studies of tumors
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note